2024-10-18 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc. is a global biopharmaceutical company that researches, develops, and markets a broad range of pharmaceuticals. 

**Performance Analysis:**

1. **Relative Performance:** ABBV has outperformed the S&P 500 (VOO) by **10.62%** over the period considered. This represents a **52.63%** position relative to the historical performance range. 
2. **Recent Price Action:** ABBV is trading at **$190.46** with a **5-day moving average of $193.19**, a **20-day moving average of $194.08**, and a **60-day moving average of $192.71**. This suggests some recent downward price pressure. 
3. **Technical Indicators:** 
    * **RSI (46.37)**: ABBV is currently in a neutral territory, indicating neither overbought nor oversold conditions.
    * **PPO (-0.26)**:  The PPO is negative, suggesting a potential for a downward price movement.
    * **Delta_Previous_Relative_Divergence (-10.8)**: Negative divergence suggests a potential slowdown in price momentum.
    * **Expected Return (1.85837839125%)**:  This indicates a potential for an upside in the stock, particularly compared to the S&P 500 over the next 5 years. 

4. **Earnings Performance:** 
    * **Most Recent Earnings:** AbbVie reported **$2.65 EPS** for the quarter ending 2024-07-25, surpassing the analyst expectation of **$2.57**. This suggests the company is performing well in the current market.

5. **News and Recent Issues:** 
    * **Recent Market Outlook:**  Analysts are generally positive on AbbVie, citing the company's strong drug portfolio, particularly Humira, and its commitment to research and development. 
    * **Analyst Opinions and Performance Highlights:** According to FINBOLD, the average analyst price target for ABBV is **$198.96** with a potential upside of **4.46%**. The company is also considered a dividend aristocrat, paying consistently high dividends for several years. 

**Conclusion:**

ABBV is a fundamentally strong company with a track record of steady growth and high dividend payouts. While recent price action suggests some downward pressure, the company's strong earnings and positive analyst sentiment indicate a potential for continued growth in the future.  The technical indicators, however, suggest a short-term cautionary stance. Overall, ABBV presents an opportunity for investors seeking both capital appreciation and consistent income. Further research and analysis are recommended before making any investment decisions. 
